NCT00697125View on ClinicalTrials.gov

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 1993

Primary Completion Date

July 31, 1994

Study Completion Date

July 31, 1994

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

BIOLOGICAL

HBV-MPL vaccine (208129)

BIOLOGICAL

Hepatitis B vaccine, experimental formulation

Intramuscular injection, 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00697125 - Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants | Biotech Hunter | Biotech Hunter